ArticleBiological psychiatry2026
The Mechanisms by Which RhoA Activity and Associated Synaptic Effects Are Controlled by the DISC1 Scaffolding-Like Protein.
Article in Biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundARHGEF11 encodes PDZ-RhoGEF, a RhoA-specific activator enriched in dendritic spines. Profiling studies have implicated increased PDZ-RhoGEF activity in causing dysfunction of the dorsolateral prefrontal cortex in individuals with bipolar disorder, including dendritic spine loss. This suggests that biochemical mechanisms that attenuate excessive PDZ-RhoGEF activity could be critical for maintaining baseline RhoA activity and proper neural phenotypes. The DISC1 scaffolding protein is able to directly bind PDZ-RhoGEF. However, the mechanisms by which DISC1's interaction with PDZ-RhoGEF restricts downstream RhoA activation with potential effects on dendritic spine stability remain fully unknown.
methodsEnzyme activity assays, protein domain mapping, subcellular fraction, and viral-mediated gene transfer were used to delineate the biochemical mechanisms by which DISC1 controls PDZ-RhoGEF's ability to bind to, and activate, RhoA. Imaging and analysis investigated the mechanisms by which DISC1 controls the effects of PDZ-RhoGEF on spine phenotypes.
resultsHere, we identified 2 biochemical processes by which PDZ-RhoGEF-mediated RhoA activation is inhibited by DISC1: 1) DISC1 sequesters RhoA from PDZ-RhoGEF, and 2) DISC1 directly reduces PDZ-RhoGEF's catalytic activity. Furthermore, we demonstrate that interfering with DISC1's ability to bind to PDZ-RhoGEF causes a multifold increase in RhoA activation and dendritic spine destabilization. Finally, we show that in vivo DISC1 knockdown increases the biochemical signatures of RhoA activation.
conclusionsExcessive PDZ-RhoGEF-mediated RhoA activation in the prefrontal cortex has been implicated in contributing to dendritic spine loss in bipolar disorder. Thus, our mechanistic findings have potential translational significance in understanding the pathophysiology of disease-mediated dendritic spine destabilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.